1623 Capital’s Intellia Therapeutics NTLA Stock Holding History

1623 Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,117	Closed	-$213K	–	45
2022 Q2	$213K	Hold	4,117	–	–	0.13%	44
2022 Q1	$299K	Buy	+4,117	New	+$349K	0.15%	46
2021 Q4	–	Sell	-2,300	Closed	-$309K	–	65
2021 Q3	$309K	Sell	2,300 -941	-29%	-$142K	0.12%	64
2021 Q2	$525K	Sell	3,241 -227	-7%	-$17.7K	0.2%	49
2021 Q1	$278K	Buy	+3,468	New	+$233K	0.11%	55

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

1623 Capital's NTLA Position: Q3 2022 in Review

1623 Capital sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 4,117 shares — an estimated $213K sold.

1623 Capital first reported a position in NTLA in Q1 2021 and held it in 5 quarters. The position peaked at $525K in Q2 2021. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

1623 Capital reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
1623 Capital sold 4,117 Intellia Therapeutics shares in Q3 2022, an estimated $213K.
1623 Capital first reported a position in Intellia Therapeutics in Q1 2021 and held it in 5 quarters.
1623 Capital's Intellia Therapeutics position peaked at $525K in Q2 2021.
319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on 1623 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.